Medtronic (MDT) Launches Exchange Offer To Complete Diabetes Business Separation

• Medtronic (NYSE:MDT) has launched an exchange offer to spin off most of its MiniMed Group diabetes business.
• The move advances Medtronic's plan to exit diabetes and focus on cardiovascular, neuroscience, and surgical devices.
• Medtronic has started a collaboration with Sonus Microsystems to deploy AI-powered wearable ultrasound for maternal health monitoring in Kenya.
• The MiniMed exchange offer and new Sonus AI ultrasound partnership give investors fresh context for Medtronic's reshaped portfolio and priorities. We have also spotted 5 other big wins worth knowing about at Medtronic.

For investors tracking how AI and medical devices intersect, the wider healthcare AI trend is worth exploring through 39 healthcare AI stocks.

Medtronic, a US medical equipment group with a market value of about $120.0 billion, focuses on device-based therapies used by hospitals and clinicians across cardiovascular, neuroscience, surgical and other care settings. This gives the latest portfolio shift and AI effort direct ties to front-line patient treatment.

Does the team leading Medtronic have what it takes? See our full breakdown of the management team's track record and compensation.

Medtronic sharpens its focus while testing AI in new care settings

For Medtronic, the MiniMed exchange offer pushes the Diabetes spin off described in the Narrative from concept to execution, which tightens the focus on higher margin cardiovascular, neuroscience and surgical therapies while also exposing the operational risks flagged around portfolio separation. The Sonus wearable ultrasound trial lines up with the Narrative theme that digital health, sensors and AI enabled ecosystems could support procedure volume and share gains, but it also adds another project where execution, clinical data and adoption will need to justify the extra spend.

See how these catalysts shape Medtronic's path to a $98.00 fair value.

From here, one practical checkpoint is the completion of the MiniMed exchange offer and final separation timing, alongside the first reported field results from the Kenya preeclampsia study. Investors can watch these developments as concrete evidence of whether Medtronic’s portfolio reshaping and AI partnerships are translating into measurable progress rather than just adding complexity.

Add Medtronic to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com